ClinicalTrials.gg
RecruitingNCT07218146DLLEVATEUpdated Oct 16, 2026

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

A Phase 3 interventional study of ZL-1310 and Investigator's Choice of Therapy in Small-cell Lung Cancer, sponsored by Zai Lab (Shanghai) Co., Ltd.. Recruiting at 165 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 16, 202618 sites added8 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
48th of 550
480 · median 55
Started
2025
with 39 others
Phase 3
50 of 629
11 open now
Primary completion
2028-06
later than 116 of 181 live
Registered
596th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 48th largest by planned enrollment of the 550 interventional ones that give a count, is one of 40 that started in 2025, is one of 50 in phase 3, reaches primary completion later than 116 of the 181 other live ones, and was the 596th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

03

Conditions studied

  • Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 18 years, or considered an adult by local regulations, at the time of consent
  • Signed
  • or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed.
  • according to v1.1 as assessed by the investigator.
  • Participants with a history of treated and stable or untreated and asymptomatic based on criteria per protocol.
  • Adequate organ and marrow function
  • Eastern Cooperative Group () performance status of 0 or 1
  • of at least 3 months
  • Participants must be willing to undergo a tumor or provide archived tumor tissue sample at Screening
  • Participants must be willing and able to comply with protocol for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Received more than one for Extensive-Stage SCLC.
  • Received any prior ADC with topoisomerase 1 inhibitor payload
  • Participants with another known with exceptions defined in the protocol.
  • History or suspected ILD/pneumonitis based on criteria per protocol
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
  • Receipt of anti-cancer treatment known to treat cancers within 3 weeks before the first dose of study treatment.
  • Prior radiotherapy before study treatment based on criteria per protocol
  • Unresolved toxicity of Grade >/= 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation.
  • Known infection or active infection defined in the protocol.
  • active cardiovascular disease or history of arterial thromboembolic event within 6 months prior to the first dose of study treatment based on criteria per protocol.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Arm 1

    ZL-1310 as a single agent

    Drug: ZL-1310

  • Active comparator
    Arm 2

    Investigator's Choice of Therapy

    Drug: Investigator's Choice of Therapy

Interventions

  • ZL-1310 as a single-agent

  • DrugInvestigator's Choice of Therapy

    Topotecan or Amrubicin

06

What researchers measure

Primary outcomes

  1. Confirmed objective response rate (ORR) assessed by Blinded Independent Central Review of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  2. Overall survival of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

Secondary outcomes

  1. Duration of response (DoR) assessed by BICR and by the investigator per RECIST v1.1 of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  2. Progression-free survival (PFS) assessed by BICR and by the investigator per RECIST v1.1 of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  3. Confirmed ORR assessed by the investigator per RECIST v1.1 of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  4. Time to response (TTR) assessed by BICR and by the investigator per RECIST v1.1 of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  5. Confirmed CNS response assessed by BICR per Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  6. Occurrence of treatment-emergent adverse events (TEAEs) of ZL-1310 compared to Investigator's Choice Therapy (ICT)

    Time frame: up to 30 months

  7. Changes from baseline in quality of life related parameters of ZL-1310 compared to Investigator's Choice Therapy (ICT) using EQ-5D-5L

    Time frame: up to 30 months

  8. Changes from baseline in quality of life related parameters of ZL-1310 compared to Investigator's Choice Therapy (ICT) using EORTC-QLQ-C30

    Time frame: up to 30 months

  9. Changes from baseline in quality of life related parameters of ZL-1310 compared to Investigator's Choice Therapy (ICT) using EORTC-QLQ-LC13

    Time frame: up to 30 months

07

Study locations

165 of 165 sites recruiting

Showing the first 100 of 165 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 31 months is close to that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 20, 2025
StartActual
Nov 30, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 8 sites removed
Show 18 added (5 Japan, 4 Greece, 3 Turkey (Türkiye), 2 France, 2 Germany, 1 Austria, 1 Spain)
  • Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) · Vienna, Austria
  • Centre Leon-Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est · Lyon, France
  • Hopital Nord Guillaume-et-Rene-Laennec CHU de Nantes · Saint-Herblain, France
  • Krankenhaus Koeln-Merheim · Cologne, Germany
  • Studiengesellschaft Haemato-Onkologie Hamburg, Prof. Laack und Partner · Hamburg, Germany
  • Sotiria General Hospital of Athens · Athens, Greece
  • University General Hospital of Patras · Rio, Greece
  • NOSILEFTIKI A.E. - Saint Luke's Clinic · Thessaloniki, Greece
  • European Interbalkan Medical Center · Thessaloniki, Greece
  • Kyushu Medical Center · Fukuoka, Japan
  • Kyushu University Hospital · Fukuoka, Japan
  • Hiroshima University Hospital · Hiroshima, Japan
  • National Cancer Center Hospital East · Kashiwa, Japan
  • Osaka International Cancer Institute · Osaka, Japan
  • Fundación Instituto Valenciano de Oncología · Valencia, Spain
  • Baskent University Adana Turgut Noyan Application and Research Center Kisla Health Campus · Adana, Turkey (Türkiye)
  • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
  • Sakarya University - Faculty of Medicine · Sakarya, Turkey (Türkiye)
Show 8 removed
  • Kyushu Medical Center · Fukuoka, Japan
  • Kyushu University Hospital · Fukuoka, Japan
  • Hiroshima University Hospital · Hiroshima, Japan
  • Osaka International Cancer Institute · Osaka, Japan
  • Fundación Instituto Valenciano de Oncología · Valencia, Spain
  • Baskent University Adana Turgut Noyan Application and Research Center Kisla Health Campus · Adana, Turkey (Türkiye)
  • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
  • Sakarya University - Faculty of Medicine · Adapazarı, Turkey (Türkiye)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    18 sites added, 8 sites removed
    Show 18 added (5 Japan, 4 Greece, 3 Turkey (Türkiye), 2 France, 2 Germany, 1 Austria, 1 Spain)
    • Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH) · Vienna, Austria
    • Centre Leon-Berard (CLB) - Centre de Recherche en Cancerologie Lyon-Est · Lyon, France
    • Hopital Nord Guillaume-et-Rene-Laennec CHU de Nantes · Saint-Herblain, France
    • Krankenhaus Koeln-Merheim · Cologne, Germany
    • Studiengesellschaft Haemato-Onkologie Hamburg, Prof. Laack und Partner · Hamburg, Germany
    • Sotiria General Hospital of Athens · Athens, Greece
    • University General Hospital of Patras · Rio, Greece
    • NOSILEFTIKI A.E. - Saint Luke's Clinic · Thessaloniki, Greece
    • European Interbalkan Medical Center · Thessaloniki, Greece
    • Kyushu Medical Center · Fukuoka, Japan
    • Kyushu University Hospital · Fukuoka, Japan
    • Hiroshima University Hospital · Hiroshima, Japan
    • National Cancer Center Hospital East · Kashiwa, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    • Fundación Instituto Valenciano de Oncología · Valencia, Spain
    • Baskent University Adana Turgut Noyan Application and Research Center Kisla Health Campus · Adana, Turkey (Türkiye)
    • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
    • Sakarya University - Faculty of Medicine · Sakarya, Turkey (Türkiye)
    Show 8 removed
    • Kyushu Medical Center · Fukuoka, Japan
    • Kyushu University Hospital · Fukuoka, Japan
    • Hiroshima University Hospital · Hiroshima, Japan
    • Osaka International Cancer Institute · Osaka, Japan
    • Fundación Instituto Valenciano de Oncología · Valencia, Spain
    • Baskent University Adana Turgut Noyan Application and Research Center Kisla Health Campus · Adana, Turkey (Türkiye)
    • Ankara Bilkent City Hospital · Ankara, Turkey (Türkiye)
    • Sakarya University - Faculty of Medicine · Adapazarı, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07218146
Collaborators
Zai Lab (US) LLC
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Nov 30, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

ZL-1310-003 Study Team
Contact
study-ZL-1310-003@zailaboratory.com
650-360-1601

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zocilurtatug Pelitecan

Start the discussion